Newswire (Published: Tuesday, January 21, 2020, Received: Tuesday, January 21, 2020, 7:00:11 PM CST)

Word Count: 480

2020 JAN 21 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Daily -- Investigators publish new report on Oncology - Prostate Cancer. According to news originating from Nathan, Australia, by NewsRx correspondents, research stated, “Androgen deprivation therapy (ADT) has broad application in the treatment of prostate cancer (PC) and is associated with numerous, debilitating adverse effects. Increasing use of ADT for PC, longer timeframe for treatment (increased uptake of PSA testing and earlier diagnosis), as well as improved survival and an ageing population, means patients can live for a considerable period of time on or after ADT, experiencing these adverse effects.”

Our news journalists obtained a quote from the research from Griffith University, “A number of systematic reviews of adverse effects of ADT for PC exist; however, no single systematic review has previously examined the evidence for all adverse effects, including newer forms of ADT. A systematic review of existing systematic reviews of ADT for PC was conducted (2010-February 2019), as per Cochrane guidelines, to identify the highest level of risk/incidence evidence available, supplemented by evidence drawn from individual studies where no systematic review existed. Incidence data was generated for 19 adverse effect subgroups, classified according to the common terminology criteria for adverse events (CTCAE). Incidence of adverse effects provides valuable information for future burden of disease studies. This information can better guide clinical management to reduce symptoms for patients and assist patients to make more informed decisions about their treatment, potentially improving disease outcomes. It also highlights the importance of supportive care for PC patients receiving ADT and their carers.”

According to the news editors, the research concluded: “For analysts conducting economic evaluations, the inclusion of adverse effects in PC decision analytic models can provide more comprehensive and accurate information for decision makers.”

For more information on this research see: Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: a systematic literature review. Supportive Care In Cancer, 2020;():. Supportive Care In Cancer can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA. (Springer -; Supportive Care In Cancer -

The news correspondents report that additional information may be obtained from K. Edmunds, Centre for Applied Health Economics, Griffith University, Nathan, QLD, Australia. Additional authors for this research include H. Tuffaha, D.A. Galvao, P. Scuffham and R.U Newton.

The direct object identifier (DOI) for that additional information is: This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

The publisher’s contact information for the journal Supportive Care In Cancer is: Springer, 233 Spring Street, New York, NY 10013, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)


Griffith University


Information and Media


Australia and New Zealand
North America
United States
New York
New York City


Science and Technology
      Scientific Research
            Medical Research
                  Clinical Outcomes
Entertainment and the Arts
and Poetry
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
                  Clinical Outcomes
      Treatments and Therapies